this assay procedure has been used to monitor simultaneously the plasma levels of neostigmine ( 4.7 to 33 ng per ml ) and pyridostigmine ( 2.7 to 18.6 ng per ml ) of a myasthenic patient over a period of twelve hours with repeated dosing of neostigmine bromide ( 30 mg ) and pyridostigmine bromide ( 60 mg ) .
C0027679
neostigmine
C0282261
neostigmine bromide